Hansoh Pharmaceutical Group Company Limited (3692.HK)
3692.HK Stock Price Chart
Explore Hansoh Pharmaceutical Group Company Limited interactive price chart. Choose custom timeframes to analyze 3692.HK price movements and trends.
3692.HK Company Profile
Discover essential business fundamentals and corporate details for Hansoh Pharmaceutical Group Company Limited (3692.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
14 Jun 2019
Employees
8.99K
Website
https://www.hspharm.comCEO
Huijuan Zhong
Description
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
3692.HK Financial Timeline
Browse a chronological timeline of Hansoh Pharmaceutical Group Company Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 Mar 2026
Dividend declared on 22 Sept 2025
A dividend of $0.23 per share was announced, adjusted to $0.23. The dividend will be paid on 30 Oct 2025.
Earnings released on 18 Aug 2025
EPS came in at $0.58 surpassing the estimated $0.39 by +47.30%, while revenue for the quarter reached $8.10B , beating expectations by +13.23%.
Dividend declared on 3 Jul 2025
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 25 Jul 2025.
Earnings released on 24 Mar 2025
EPS came in at $0.30 surpassing the estimated $0.24 by +21.72%, while revenue for the quarter reached $6.12B , beating expectations by +4.00%.
Earnings released on 27 Aug 2024
EPS came in at $0.49 surpassing the estimated $0.42 by +17.95%, while revenue for the quarter reached $6.99B , beating expectations by +4.44%.
Earnings released on 26 Mar 2024
EPS came in at $0.36 surpassing the estimated $0.24 by +49.21%, while revenue for the quarter reached $6.19B , beating expectations by +1.71%.
Earnings released on 31 Aug 2023
EPS came in at $0.23 falling short of the estimated $0.25 by -5.67%, while revenue for the quarter reached $4.88B , missing expectations by -2.40%.
Earnings released on 27 Mar 2023
EPS came in at $0.25 surpassing the estimated $0.24 by +2.75%, while revenue for the quarter reached $5.64B , missing expectations by -10.46%.
Earnings released on 26 Aug 2022
EPS came in at $0.26 falling short of the estimated $0.26 by -0.39%, while revenue for the quarter reached $5.19B , missing expectations by -1.70%.
Earnings released on 29 Mar 2022
EPS came in at $0.29 surpassing the estimated $0.28 by +2.76%, while revenue for the quarter reached $6.78B , missing expectations by -1.03%.
Earnings released on 26 Aug 2021
EPS came in at $0.26 falling short of the estimated $0.31 by -17.25%, while revenue for the quarter reached $5.28B , missing expectations by -14.67%.
Earnings released on 30 Mar 2021
EPS came in at $0.27 falling short of the estimated $0.31 by -12.39%, while revenue for the quarter reached $5.59B , missing expectations by -5.42%.
3692.HK Stock Performance
Access detailed 3692.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.